TD Cowen initiated coverage on shares of CeriBell (NASDAQ:CBLL – Free Report) in a report released on Tuesday morning, MarketBeat reports. The brokerage issued a buy rating and a $31.00 price objective on the stock.
Separately, William Blair started coverage on CeriBell in a report on Tuesday. They set an “outperform” rating on the stock. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $31.00.
Get Our Latest Report on CeriBell
CeriBell Price Performance
CeriBell Company Profile
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
See Also
- Five stocks we like better than CeriBell
- Insider Trading – What You Need to Know
- AMD: The AI Disruptor – Is It Time to Follow Big Tech’s Lead?
- Learn Technical Analysis Skills to Master the Stock Market
- Analysts Signal Big Upside: Top 3 Stocks to Watch Right Now
- 3 Fintech Stocks With Good 2021 Prospects
- Bears Misjudged These 3 ETFs: Where Investors Can Find Upside
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.